Thermo Fisher Scientific Inc., a Waltham company that focuses on analytical technologies, specialty diagnostics, and laboratory products and services, said revenue rose 4 percent to $3.24 billion, a second-quarter record.
Second quarter net income was $277.4 million. Adjusted earnings per share grew 8 percent to a second quarter record of $1.32, the company said in a press release.
“We delivered another solid quarter, with good performance on the top and bottom line,” Marc N. Casper, president and chief executive of Thermo Fisher Scientific, said in a statement.
“It was a stand-out quarter for innovation, highlighted by our industry-leading mass spectrometry launches at ASMS. We unveiled three new-generation Thermo Scientific platforms – the breakthrough Orbitrap Fusion Tribrid, and the Quantiva and Endura triple quads – to provide a broad set of customers with exceptional levels of performance, speed, and ease of use. We also continued to strengthen our R&D capabilities in Asia-Pacific by establishing our new China Innovation Center in Shanghai – another example of our focus on innovating to meet our customers’ needs. In terms of our pending acquisition of Life Technologies, I’m pleased to report that the integration planning teams are making great progress. We’re excited about the opportunities ahead and look forward to closing the transaction early in 2014.”
Thermo Fisher said it is also updating its full year revenue guidance to a new range of $12.83 to $12.95 billion from its previous range of $12.84 to $13.00 billion, “reflecting increased headwinds from currency exchange rates. This results in 3 percent to 4 percent revenue growth over 2012, consistent with previous guidance. The company is also updating its adjusted EPS guidance for the full year, raising the low end by $0.02 to a new range of $5.29 to $5.39, primarily reflecting solid operating performance, partially offset by the impact of currency exchange and a slightly higher share count. Consistent with previous guidance, adjusted EPS growth remains at 7 percent to 9 percent over the prior year. The 2013 guidance does not include the pending acquisition of Life Technologies or the impact of related financing activities.”